Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,062 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Recruiting No phase listed Observational

Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy

NCT06891209
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Not listed Not applicable Interventional

Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma

NCT04424472
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Ultrasonography
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 22, 2026, 7:23 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

NCT00417677
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Combination of Temsirolimus and Sunitinib
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need

NCT03136601
View directory record Official record
Conditions
Overactive Bladder
Interventions
PTNS maintenance
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional

Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

NCT00240019
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Addition of furosemide 20 mg oral bid to baseline regimen
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Santa Clara, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2006 · Synced Oct 22, 2026, 7:23 AM EDT
Completed No phase listed Observational

Oxygen Desaturation During Hemodialysis

NCT02501044
View directory record Official record
Conditions
Renal Disease, Hypoxia
Interventions
Not listed
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional Results available

Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap

NCT02604264
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
ClearGuard HD end cap
Device
Lead sponsor
Pursuit Vascular, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Not applicable Interventional

Using Shared Decision Making to Improve Kidney Transplantation Rates

NCT06141499
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure
Interventions
Provider educational materials, Patient letters
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 1 Interventional

Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

NCT00656734
View directory record Official record
Conditions
Kidney Cancer
Interventions
MDX 1411
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Boston, Massachusetts • Detroit, Michigan • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 22, 2026, 7:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709
View directory record Official record
Conditions
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions
BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

NCT00330564
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
Interventions
SU011248
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 22, 2026, 7:23 AM EDT
Not yet recruiting No phase listed Observational

A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

NCT07814872
View directory record Official record
Conditions
Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Glioma, Ovarian Neoplasms, Stomach Neoplasms
Interventions
Not listed
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
Not listed
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Recruiting No phase listed Observational

Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry

NCT04829175
View directory record Official record
Conditions
Stress Urinary Incontinence, Pelvic Organ Prolapse
Interventions
Intervention
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
4
States / cities
New Haven, Connecticut • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Recruiting Not applicable Interventional

Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use

NCT04128709
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Urodynamics Testing
Device
Lead sponsor
Christopher Cooper
Other
Eligibility
1 Year to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

NCT01487109
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
CTP-499, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
49
States / cities
Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

NCT01136733
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 22, 2026, 7:23 AM EDT
Suspended Phase 1 Interventional

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

NCT06049576
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Myrciaria dubia Prebiotic Supplement, Nivolumab
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Utilization of a Web-Based Application to Improve Patient Health Literacy and Reduce Clinic Visit Times in Holmium Laser Enucleation of the Prostate (HoLEP) Procedures and Kidney Stone Surgery

NCT07580391
View directory record Official record
Conditions
Kidney Stone, Benign Prostatic Hyperplasia
Interventions
WellPrept, Standard Care
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Withdrawn No phase listed Observational

Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)

NCT01468506
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 22, 2026, 7:23 AM EDT
Completed No phase listed Observational

Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry

NCT02852252
View directory record Official record
Conditions
Bladder Cancer, Gastric Cancer
Interventions
OTL38, ICG
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Early Phase 1 Interventional

Rituximab in the Treatment of Idiopathic Membranous Nephropathy

NCT00405340
View directory record Official record
Conditions
Membranous Nephropathy
Interventions
Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Results available

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

NCT05656040
View directory record Official record
Conditions
End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Edgewater, Florida • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 22, 2026, 7:23 AM EDT
Completed Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 7:23 AM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

NCT07187778
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Pembrolizumab, Belzutifan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 7:23 AM EDT